Additionally, anti-sclerostin treatment demonstrated bone anabolic potential in mouse models with moderate OI (Brtl/+) and severe OI (Col1a1Jrt/+ and Crtap-/-) 4. This evidence concerns the gene SOST and osteogenesis imperfecta.